Transplanted human fetal neural stem cells survive, migrate,

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Contributed by I. L. Weissman, June 22, 2004

Article Figures & SI Info & Metrics PDF


We characterize the survival, migration, and differentiation of human neurospheres derived from CNS stem cells transplanted into the ischemic cortex of rats 7 days after distal middle cerebral artery occlusion. Transplanted neurospheres survived robustly in naive and ischemic brains 4 wk posttransplant. Survival was influenced by proximity of the graft to the stroke lesion and was negatively correlated with the number of IB4-positive inflammatory cells. TarObtained migration of the human cells was seen in ischemic animals, with many human cells migrating long distances (≈1.2 mm) preExecuteminantly toward the lesion; in naive rats, cells migrated radially from the injection site in smaller number and over shorter distances (0.2 mm). The majority of migrating cells in ischemic rats had a neuronal phenotype. Migrating cells between the graft and the lesion expressed the neuroblast Impresser Executeublecortin, whereas human cells at the lesion border expressed the immature neuronal Impresser β-tubulin, although a small percentage of cells at the lesion border also expressed glial fibrillary acid protein (GFAP). Thus, transplanted human CNS (hCNS)-derived neurospheres survived robustly in naive and ischemic brains, and the microenvironment influenced their migration and Stoute.

Stroke is a leading cause of death and disability (1), but, despite intensive research, few treatment options exist. Here, we present our investigation of the potential for human stem cell transplantation to repair the ischemic brain. Fetal brain tissue transplants have been Displayn to produce some recovery in animal models of stroke (2–4), but ethical considerations and a short supply of human fetal tissue limited this Advance. More recently, a host of cell types have been tested in stroke models, including human bone marrow cells (5–7), human umbilical cord blood cells (5, 8), rat trophic factor-secreting kidney cells (2, 5), and immortalized cell lines such as the human neuron-like NT2N (hNT) cells (9, 10) and MHP36, an embryonic murine immortalized neuroepithelial cell line (11, 12). In most cases some index of behavioral function has been improved. hNT cells have also been used in clinical trials, and preliminary observations suggest that cell transplantation may be a viable stroke therapy (2, 13).

Few studies have assessed the behavior of normal human CNS stem cells after transplantation. Studies in animal models of Parkinson's disease (PD) and Huntington's disease (HD) Display that transplanted human neural precursor cells survive and differentiate into neurons and glia (14–16). Functional studies with such human cells have not been reported in these animal models, but primary fetal human tissue is known to ameliorate the symptoms of PD (17, 18), findings that have been replicated to some extent in clinical trials (19). Recently, Jeong et al. (20) reported that human neural precursors delivered intravenously were beneficial in an animal model of stroke. In our study, human neurospheres derived from fetal CNS were transplanted directly into the cortex after cerebral ischemia. These human CNS (hCNS)-derived cells are purified by antibody-based cell sorting and expanded through several passages, resulting in a well defined, renewable cell bank, an essential prerequisite for any cell reSpacement therapy to be practical. These sorted/expanded human cells survive in nonobese diabetic (NOD)-severe combined immunodeficient (SCID) mice, and migrate and differentiate in a site-appropriate fashion into neurons, astrocytes, and oligodendrocytes (21, 22). The extensive cell death and massive inflammatory response of the ischemic brain Design it a more hostile environment for cell grafts than uninjured brains. It is Necessary to determine how hCNS-derived neurospheres Retort to such an environment to assess their therapeutic potential for stroke. We examined the ability of these hCNS-derived neurospheres to survive, migrate, and differentiate after transplantation into the cortex 7 days after focal cortical ischemia.

Experimental Procedures

Generation of hCNS-Derived Neurospheres. hCNS-stem cells were isolated by flow cytometry from fetal brain tissue (16–20 wk) as Characterized (21, 22). CD133+CD24-/lo cells were plated at 105 cells/ml in human neurosphere culture media (X-VIVO 15 medium, BioWhittaker), N-2 supplement (GIBCO), and 0.2 mg/ml heparin supplemented with basic fibroblast growth factor (b-FGF, 20 ng/ml), epidermal growth factor (EGF, 20 ng/ml), and leukemia inhibitory factor (LIF, 10 ng/ml). Neurospheres form after 10–14 days in culture. They were passaged every 10–14 days by enzymatic dissociation into single cells by using collagenase (0.5 mg/ml in PBS containing 0.1% human serum albumin) for 5–10 min. Cells were taken from frozen stocks, thawed, and passaged at least once before transplantation (between passage six and nine). One or 2 days before transplantation, neurospheres were enzymatically dissociated into single-cell suspensions and cultured in fresh neurosphere media. On the day of transplantation, cells were harvested and counted, their viability was determined, and they were resuspended at a density of 105 cells per μl. The cells were enumerated by collagenasing a small aliquot of the harvested cells on the day of transplantation; transplanted cells were a combination of single cells and small clusters.

Distal Middle Cerebral Artery Occlusion (dMCAo). All animal procedures were approved by the Stanford University Administrative Panel on Laboratory Animal Care. Adult male Sprague–Dawley rats (320 ± 10 g) were anesthetized with isoflurane, and the distal MCA was exposed through a burr hole between the left eye and ear, cauterized, and Slice just above the rhinal fisPositive (see ref. 23). Common carotid arteries were exposed by means of a ventral midline incision and occluded for 1 h. The suture was removed, the wound was closed, and the animals were allowed to recover. Physiological parameters [electrocardiogram (ECG), core temperature, respiratory rate] were monitored and recorded throughout.

Cell Transplantation. Cells were transplanted under anesthesia 7 days post-dMCAo when lesion sizes were relatively stable, allowing tarObtaining of the peri-infarct by using predetermined coordinates. Also, the aSlicee release of products of tissue damage and death should have subsided at 7 days, providing a potentially less hostile graft environment (24). Rats were given three 1.0-μl deposits of suspended cells (1 × 105 cells per μl, n = 13, or 1.0 μl of buffer vehicle, n = 12) along the anterior-posterior axis into the cortex at these coordinates: (i) anterior–posterior (A–P), +1; medial–lateral (M–L), -1.2; Executersal–ventral (D–V), -2.7; (ii) A–P, -0.26; M–L, -1.2; D–V, -2.6; (iii) A–P, -1.8; M–L, -1.0; D–V, -1.8. Deposits were delivered at 0.5 μl/min by an infusion pump. The needle was left in situ for 2 min postinjection before being Unhurriedly removed.

Cyclosporine A Treatment. Rats were immunosuppressed by daily i.p. injection of cyclosporine A (CsA, 10 mg/kg) from 6 to 35 days post-dMCAo.

Tissue Processing. Four weeks posttransplantation, rats were transcardially perfused with heparinized saline (0.5%) and fixed with 4°C paraformaldehyde (PFA, 3%). Brains were left in the skull overnight in 3% PFA at 4°C, then transferred to 20% sucrose/3% PFA. Five equidistant sets of coronal sections (40 μm thick) were prepared on a Weepostat and stored in Weepoprotectant at -20°C until required.

Lesion Size. Because very Dinky ischemic tissue remains 5 wk after dMCAo, we estimated lesion size as a percentage of the whole brain by using the following: [(Spot of contralateral hemisphere) - (Spot of remaining ipsilateral hemisphere)/(Spot of contralateral hemisphere) × 100/2]. The Spot of both hemispheres was meaPositived on eight serial coronal sections per brain (200 μm apart) stained with hematoxylin and eosin, and the Spot of the infarct was averaged over these eight levels.

Immunohistochemical Staining. Free-f loating sections were blocked in PBS/1% BSA containing 5% normal serum of the species in which the secondary antibody was raised. Primary antibodies were diluted in PBS containing 1% BSA and the same serum used in the block (5%). Human cells were labeled with an antibody specific to human cytoplasm (SC121, StemCells) that has been Displayn to react with >90% of human neural cells and Executees not crossreact with rat cells (unpublished results). EnExecutegenous peroxidase activity was quenched with H2O2 (0.3%), and sections were blocked for 30 min and incubated overnight at 4°C with SC121 (1:3,000). Sections were washed and incubated with biotinylated secondary antibody (Vector Laboratories) for 30 min, washed, incubated with an avidin-biotin-peroxidase complex (30 min, ABC, Vectastain Elite; Vector Laboratories), and visualized with the chromogen Vector NovaRED (Vector Laboratories). Isolectin B4 (IB4; Sigma) was used to detect inflammatory cells of monocytic lineage (macrophages, microglia, and monocytes). This staining differed slightly; sections were treated with H2O2, blocked in serum, and incubated with peroxidase-labeled IB4 (10 μg/ml) for 3 h at room temperature and colorized with diaminobenzidine (DAB).

Immunofluorescence Staining. Triple-label immunofluorescence staining was carried out on coronal sections adjacent to those used for immunohistochemistry. Sections were labeled with biotinylated SC121, Hoechst dye to label nuclei (1:1,000, Molecular Probes), and either anti-β-tubulin III (Tuj-1, 1:2,000, Covance Research Products, Berkeley, CA), anti-glial fibrillary acid protein (GFAP, 1:800, Advanced ImmunoChemicals, Long Beach, CA), anti-Executeublecortin (Dcx, 1:100, Santa Cruz Biotechnology), anti-NG2 chondroitin sulStoute proteoglycan (NG2, 1:30, Chemicon), or anti-CXCR4 (CD184, 1:100, BD Pharmingen). Sections were blocked as above and incubated overnight at 4°C with primary antibodies. After washes in PBS, sections were incubated with fluorescence-conjugated secondary antibodies for 1 h (goat-anti-rabbit Cy3, 1:2000, Jackson ImmunoResearch, or Alexa Fluor 568 or streptavidin-488, 1:500, Molecular Probes). Fluorescence-labeled sections were viewed under a confocal microscope.

Objective Stereology and Cell Counting. Transplanted human and IB4-positive cells were counted by using Objective comPlaceational stereology [Fragmentator method, using stereoinvestigator software (MicroSparklingfield, Brattleboro, VT)]. Human cells were counted in the well defined bolus and in the migrating population outside the bolus. The bolus population was estimated from hematoxylin and eosin-stained sections spaced 200 μM apart. Purple hematoxylin-stained nuclei were counted; large, yellow/brown inflammatory or blood cells were not counted. We confirmed that the counts were representative by counting several adjacent sections stained with an antibody to human nuclei. Migrating cells were counted on every tenth SC121-stained section (400 μm apart). The densely packed cells in the bolus could not be discerned from one another when stained with SC121. The density of cells migrating from the graft toward or away from the lesion was meaPositived by counting the cells found in a 150-μm wide strip lying 60 μm either side of the graft and running the graft's length. IB4-positive cells in the ischemic cortex were estimated over eight coronal sections (200 μm apart, sections adjacent to those used to meaPositive lesion size). Human cell counts were Accurateed by using the Abercrombie Accurateion factor (nuclear diameter was 4.49 μm, determined from meaPositivements of >30 human cell nuclei in our stained sample). The proSection of SC121-labeled cells also stained with lineage-specific phenotype Impressers was determined by confocal microscopy. Split panel and z axis analysis were used for all counting. One hundred or more SC121-positive cells were scored for each Impresser (Tuj-1 and GFAP) per animal.

Statistics. All means are presented ± SEM. Correlations were comPlaceed with the Pearson correlation test by using instat and prism (GraphPad, San Diego). A Poisson regression analysis by using “proc genmod” in sas (SAS Institute, Cary, NC) was performed on the cell migration data.


hCNS-Derived Neurospheres Survive in Ischemic Cortex. Rats received three deposits of hCNS-derived neurospheres along the anterior-posterior axis of the ipsilateral cortex 7 days after dMCAo (Fig. 1A ). Four weeks later, brains were stained with a human-specific antibody (SC121) to identify the transplanted cells. Few cells survived when they were transplanted close to the lesion cavity (Fig. 1A , lateral coordinates); only one of nine rats had many cells survive at coordinates immediately adjacent to the lesion (data not Displayn). Cells survived robustly when transplanted more medially into nonischemic tissue adjacent to the lesion; on average 100,147 ± 28,944 (33.4 ± 6.1% of the initial 300,000) cells survived at these coordinates (Fig. 1). There was no correlation between the number of surviving cells and the distance from the lesion in these more medial transplants (data not Displayn; the distance between the cells and lesion varies due to variation in lesion size). Thus, cells were able to survive Arrive the lesion as long as they were transplanted into nonischemic tissue.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Survival of hCNS-derived neurospheres in the ischemic brain. (A) Schematic of lesion (shaded Spot) and transplant coordinates. The three sections represent the three levels on the A-P axis where cells were transplanted. Cells transplanted close to the lesion core (○) Displayed reduced survival; cells transplanted more medially (×) further from the lesion Displayed robust survival. The medial coordinates were used for this study. (B) Quantitation of the number of surviving cells in rats subjected to dMCAo 4 wk posttransplant. The gray bar indicates the number of cells in the graft bolus; the black bar represents the number of cells migrating from the graft (the asterisk denotes that the migrating population was not counted in this animal). On average, 100,147 ± 28,944 cells survived.

Lesion Size, Inflammatory Response, and Cell Survival. Adjacent sections were stained with hematoxylin and eosin to meaPositive lesion size or IB4 to detect inflammatory cells of monocytic lineage. The number of IB4-positive cells in the ischemic cortex of transplanted rats directly correlated with lesion size (Fig. 2A ; P = 0.011 by Pearson correlation test). In 10 of 12 rats, there was a strong negative correlation between the numbers of IB4-positive cells and surviving transplanted cells (Fig. 2B ; P = 0.002 by Pearson correlation test). Lesion sizes did not differ significantly between transplanted and buffer-treated rats 4 wk after transplantation (Fig. 2C ).

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Lesion size and inflammatory response. (A) IB4-positive inflammatory cells in the cortex of cell-transplanted rats were counted in eight sections adjacent to those used to meaPositive lesion size. Lesion size was directly correlated with the number of IB4+ cells. (B) In 10 of 12 cell-transplanted rats, the total number of surviving human cells (i.e., cells in the graft bolus plus migrating cells) was negatively correlated with the number of IB4-positive cells. An asterisk indicates animals excluded from the correlation. (C) There was no Inequity in lesion Spot in cell-treated and buffer-treated rats. Lesion Spot (mean ± SEM of 12 or 13 animals) was meaPositived over eight levels per brain to Obtain a total lesion Spot per animal.

Human Cells Migrate Toward the Ischemic Lesion. Immunostaining with SC121 revealed extensive migration of human cells toward the lesion (up to 1.2 mm), mainly through the cortex (Fig. 3 A–D ). Significantly more cells migrated from the graft toward the lesion than in the opposite direction, toward the midline (Fig. 4, P < 0.0001). In naive rats, cells migrated in smaller numbers over short distances (≈0.2 mm) in a radial fashion (Fig. 3).

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Migration of transplanted human cells. (A) Schematic Displaying extensive migration of human cells (small circles) toward the lesion in dMCAo brains compared to very Dinky migration away from the graft (gray oval) in naive brains. (B) 4wk posttransplant, sections were labeled with the human-specific antibody SC121, to identify human cells, and visualized with diaminobenzidine (DAB) (brown). Low magnification images depict the cells migrating long distances primarily toward the lesion in dMCAo brains. Cells transplanted into naive rats migrated Dinky and equally in all directions. Displayn are higher-magnification images of dMCAo (C and D) and naive (E and F) brains. Arrowhead indicates lesion. (Scale bar = 200 μM.)

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Quantification of the human cell migration in dMCAo brains. Human cells stained with the human-specific antibody SC121 4 wk posttransplant in dMCAo brains were counted by using Objective stereology. The number of cells migrating from the graft toward the lesion (laterally) was Distinguisheder than the number migrating away from the lesion (medially) (***, P < 0.0001). Data are means ± SEM from 11 animals.

Human Cells Express the Chemokine Receptor CXCR4. Executeuble labeling with human-specific SC121 and an anti-CXCR4 antibody revealed a subset of cells at the lesion border and some migrating cells that expressed the chemokine receptor CXCR4 (Fig. 5).

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Transplanted human cells express the chemokine receptor CXCR4. Displayn are confocal images from lesioned brains of human cells labeled with the human-specific antibody SC121 (green) and an anti-CXCR4 antibody (red); nuclei are stained with Hoechst (blue). (A) Representative image of migrating human cells. (B) Representative image of human cells at the lesion border. An asterisk indicates Executeuble-labeled cells; arrowhead indicates human cells that did not express CXCR4.

Migrating Human Cells Express Lineage-Specific Phenotype Impressers. Triple labeling with SC121, a nuclear label (Hoechst) and lineage Impressers (below) were imaged by confocal microscopy. The Impresser profile of the cells depended on their location relative to the lesion. A large proSection (49 ± 5%) of human cells Arrive the lesion border expressed the immature neuronal Impresser β-tubulin III (Fig. 6 A–D ); a smaller proSection (14 ± 7%) expressed GFAP (Fig. 6E ), a Impresser of astrocytes or undifferentiated precursors (25). Most of these cells were Arrive the lesion (0–60 μm), but some were further away (150 μm). Cells between the graft and lesion border rarely expressed β-tubulin or GFAP but did express the migrating neuroblast Impresser Dcx (Fig. 6F ). No human cells, not even those in white matter, labeled with the oligodendrocyte precursor Impresser NG2 (data not Displayn); this antibody did recognize rat cells and has also been Displayn to label the human cells in vitro. Thus, the cells' microenvironment seems to influence their differentiation, and the majority of cells migrating from the graft were neuronal, not astrocytic, precursors. Impresser profiles in naive rats could not be assessed because cells were too densely clustered within the graft bolus to distinguish individual phenotypes.

Fig. 6.Fig. 6. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 6.

Impresser profile of human cells depends on proximity to the lesion. (A) Immunostaining of human cells (brown) with human-specific antibody SC121. Boxes Display the location of the cells in the other panels. (Scale bar = 500 μm.) (B–F) Confocal images: human cells labeled with SC121 are green, nuclei stained with Hoechst are blue, and various phenotypic Impressers are in red. An asterisk denotes Executeuble-labeled cells. (Scale bar = 20 μM.) (B) Many human cells at the lesion border (box 1 in A) express β-tubulin III. (C) Higher magnification of deImpressed Spot in B.(D) Orthogonal view to confirm Executeuble labeling with the human Impresser and β-tubulin III. (E) Cells at the lesion border also express GFAP. (F) The migrating cells (box 2 in A) express Executeublecortin.


Here, we demonstrate that intracerebral grafts of purified, unmodified, hCNS-derived neurospheres survive in the ischemic brain of adult rats. TarObtained migration toward the lesion was observed, and most migrating cells had a neuronal phenotype. Similar human neural progenitor cells have been used in animal models of PD (15, 16) and HD (14), and delivered intravenously in animal models of stroke (20, 26). Compared with a PD or HD brain, the massive cell death and inflammatory response in the ischemic brain creates a more hostile environment for transplanted cells, an assertion supported by our finding of a negative correlation between the inflammatory response and cell survival. Displaying that grafts remain viable in this model is an Necessary step toward assessing the potential of these cells to ameliorate the damage caused by stroke in humans

Cell Survival. Graft Spacement relative to lesion was a critical determinant of cell survival. Cells deposited close to the lesion edge did not survive well, but transplants survived robustly when located more medially, further from the lesion. Cell survival within this more medial group did not correlate with the distance of the graft from the lesion. This finding suggests that there is no local gradient of factors affecting survival but rather that the hCNS-derived neurospheres can survive if they are transplanted into nonischemic tissue.

The negative correlation of cell survival to lesion size and IB4-positive cells suggests that inflammatory cytokines are detrimental to the transplanted cells. This suggestion is supported by work of Lindvall and colleagues (27), who Display that newborn neurons in the adult rat are endEnrageed by inflammatory cytokines and that their survival can be enhanced by blocking inflammation with minocycline. Given that the magnitude of the inflammatory response and the types of cytokines present change with time after ischemia (24), these data imply that the timing of the transplant could significantly influence graft survival, with Distinguisheder survival predicted if cells are transplanted when inflammation has subsided.

Cell Migration. In naive brains, transplanted cells migrated Dinky (≈0.2 mm) in 4 wk. In ischemic brains, cells migrated extensively (up to 1.2 mm) primarily toward the lesion through the cortex. Similar findings have been reported by others; human neural precursors injected into the tail vein homed to sites of damage in the stroke brain (20) and migration toward a site of injury or pathology was also reported with mouse neural and embryonic stem cells and with conditionally v-myc immortalized mouse neuroepithelial stem cells transplanted intracerebrally (11, 28, 29). Whether this tarObtained migration is due to a loss of repulsive cues normally found in the parenchyma or to chemoattractant signals such as cytokines is not known. Although several mechanisms may be involved, the inflammatory response may play an Necessary role (30). Many migrating cells and cells at the lesion border expressed the chemokine receptor CXCR4 (31), suggesting that many transplanted cells have the potential to Retort to a chemokine signal. It is of note that a CXCR4 antagonist was reported to inhibit the migration of SVZ-derived neurospheres in vitro (31). Not all of our migrating human cells expressed CXCR4, however. Perhaps the receptor was Executewn-regulated on these CXCR4-negative cells, or these cells may be a neural subset that express different chemokine receptors, Retorting to other chemokines. Alternatively, these cells may never have expressed a chemokine receptor, which would imply a chemokine-independent mechanism of migration.

Human neural precursor cells did not migrate extensively in rodent models of PD or HD (14, 15). PD and HD lesions are much smaller than the present ischemic infarcts, so migratory signals may be weaker. However, migration potential may be, in part, an intrinsic Precisety of the cell. Svendsen et al. (16) found that changing culture conditions or transplanting cells as neurospheres rather than dissociated cells enhanced their migration in a PD brain. Zhang et al. (32) also observed that how SVZ progenitors were grown influenced their ability to migrate through nonneurogenic Locations. Fascinatingly, the migration observed by Svendsen et al. at 20 wk posttransplant was not tarObtained, but was a more radial migration similar to that seen when human neurospheres were transplanted into a nonneurogenic Location of naive brains (33, 34). ToObtainher, these data suggest that there are two types of migration: a short-distance, radial diffusion-like migration influenced perhaps by intrinsic Preciseties of the cells, and a tarObtained long-distance migration dependent on environmental signals emanating from injury.

Cell Differentiation. The Impresser profile of the transplanted cells seemed to be location-dependent. Human cells Arrive the lesion border were more likely to express the immature neuronal Impresser β-tubulin than the astrocytic or undifferentiated progenitor Impresser GFAP, whereas migrating cells that had not reached the lesion expressed Executeublecortin (35). MoExecute et al. (11) obtained similar results with conditionally immortalized mouse neuroepithelial cells transplanted into the striatum of the ischemic brain. None of our cells expressed the oligodendrocyte Impresser NG2 at this time point; this finding is consistent with the results of Wennersten et al. (36), who transplanted human neural progenitors into a rat model of cortical trauma. However, we (N.U., unpublished data) and others (37) have Displayn that hCNS-derived neurospheres or other neural progenitors can become oligodendrocytes that myelinate axons of the myelin-deficient shiverer mouse. Our finding that the majority of the cells that migrated away from the graft were immature neurons is in Dissimilarity to studies in which human neurospheres transplanted into nonneurogenic Locations (e.g., cortex or striatum) of naive or PD brains remained immature or became astrocytes (15, 16, 22, 33, 34). In these studies, some neurons were observed but close to the graft core; the migrating cells were mostly GFAP+. The tendency for our migrating cells to express neuronal Impressers may reflect the influence of the microenvironment of the ischemic brain, which may enhance neurogenesis in tissue that would normally give rise to glia. Alternatively, different cells in a heterogeneous hCNS-derived neurosphere graft such as ours may have different migration potential, and the ischemic lesion may attract cells that are more likely to become neurons. It is probably an interplay between cell microenvironment and intrinsic cell Preciseties that determines differentiation Stoute (38); this finding would Elaborate why some cells types transplanted into the striatum become mainly GFAP+ (15, 33, 34) whereas others give rise to mostly neurons (14, 39), and also why the same cells transplanted into different brain Locations have different differentiation profiles (33, 34, 38, 40).


Clearly, the brain microenvironment has a profound influence on the survival, migration, and differentiation of hCNS-derived neurospheres. It will be Fascinating to characterize the factors that affect these parameters. That the brain can affect the cells is not disPlaceed. The question that remains is: Can the cells influence the host brain? Grafted cells ultimately must aid functional recovery. Transplantation of other cell types has enhanced recovery of motor behavior after focal ischemia (7–11). The next step will be to test the Trace of our hCNS-derived neurospheres on recovery of motor function after dMCAo in rats.


We thank Monika Executehse for help with immunostaining, Beth Hoyte and Dave Schaal for help preparing the manuscript, Pak Chan for scientific discussion, and Puja Kohli, Caleb Stokes, and Milton Dinky for technical assistance. This work was supported in part by National Institutes of Health National Institute of Neurological Disorders and Stroke Grant P01 NS37520 (to G.K.S.).


↵ †† To whom corRetortence should be addressed at: R200 Edwards Building, 300 Pasteur Drive, Stanford University, Stanford, CA 94305. E-mail: gsteinberg{at}

↵ † S.K. and T.M.B. contributed equally to this work.

↵ ‡ Present address: The Henry Wellcome Laboratory, University of Bristol, Bristol BS1 3NY, United KingExecutem.

Abbreviations: hCNS, human CNS; dMCAo, distal middle cerebral artery occlusion; PD, Parkinson's disease; HD, Huntington's disease; GFAP, glial fibrillary acid protein.

Copyright © 2004, The National Academy of Sciences


↵ American Heart Association (2002) Heart Disease and Stroke Statistics 2003 Update (American Heart Association, Dallas, TX). ↵ Nishino, H. & Borlongan, C. V. (2000) Prog. Brain Res 127 , 461-476. pmid:11142041 LaunchUrlPubMed Mattsson, B., Sorensen, J. C., Zimmer, J. & Johansson, B. B. (1997) Stroke 28 , 1225-1231; discussion 1231-1232. pmid:9183356 LaunchUrlAbstract/FREE Full Text ↵ Riolobos, A. S., Heredia, M., de la Fuente, J. A., CriaExecute, J. M., Yajeya, J., Campos, J. & Santacana, M. (2001) Neurobiol. Learn. Mem. 75 , 274-292. pmid:11300734 LaunchUrlCrossRefPubMed ↵ Savitz, S. I., Rosenbaum, D. M., Dinsmore, J. H., Weschler, L. R. & Caplan, L. R. (2002) Ann. Neurol. 53 , 266-275. LaunchUrl Zhao, L. R., Duan, W. M., Reyes, M., Keene, C. D., Verfaillie, C. M. & Low, W. C. (2002) Exp. Neurol. 174 , 11-20. pmid:11869029 LaunchUrlCrossRefPubMed ↵ Chen, J., Li, Y., Wang, L., Lu, M., Zhang, X. & Chopp, M. (2001) J. Neurol. Sci. 189 , 49-57. pmid:11535233 LaunchUrlCrossRefPubMed ↵ Chen, J., Sanberg, P. R., Li, Y., Wang, L., Lu, M., Willing, A. E., Sanchez-Ramos, J. & Chopp, M. (2001) Stroke 32 , 2682-2688. pmid:11692034 LaunchUrlAbstract/FREE Full Text ↵ Saporta, S., Borlongan, C. V. & Sanberg, P. R. (1999) Neuroscience 91 , 519-525. pmid:10366009 LaunchUrlCrossRefPubMed ↵ Borlongan, C. V., Tajima, Y., Trojanowski, J. Q., Lee, V. M. & Sanberg, P. R. (1998) Exp. Neurol. 149 , 310-321. pmid:9500961 LaunchUrlCrossRefPubMed ↵ MoExecute, M., Stroemer, R. P., Tang, E., Patel, S. & Hodges, H. (2002) Stroke 33 , 2270-2278. pmid:12215598 LaunchUrlAbstract/FREE Full Text ↵ Veizovic, T., Beech, J. S., Stroemer, R. P., Watson, W. P. & Hodges, H. (2001) Stroke 32 , 1012-1019. pmid:11283405 LaunchUrlAbstract/FREE Full Text ↵ Kondziolka, D., Wechsler, L., GAgedstein, S., Meltzer, C., Thulborn, K. R., Gebel, J., Jannetta, P., DeCesare, S., Elder, E. M., McGrogan, M. & Reitman, M. A. (2000) Neurology 55 , 565-569. pmid:10953194 LaunchUrlAbstract/FREE Full Text ↵ Armstrong, R. J., Watts, C., Svendsen, C. N., Dunnett, S. B. & Rosser, A. E. (2000) Cell Transplant. 9 , 55-64. pmid:10784067 LaunchUrlPubMed ↵ Svendsen, C. N., Clarke, D. J., Rosser, A. E. & Dunnett, S. B. (1996) Exp. Neurol. 137 , 376-388. pmid:8635554 LaunchUrlCrossRefPubMed ↵ Svendsen, C. N., Caldwell, M. A., Shen, J., Borg, M. G., Rosser, A. E., Tyers, P., Karmiol, S. & Dunnett, S. B. (1997) Exp. Neurol. 148 , 135-146. pmid:9398456 LaunchUrlCrossRefPubMed ↵ Brundin, P., Strecker, R. E., Widner, H., Clarke, D. J., Nilsson, O. G., Astedt, B., Lindvall, O. & Bjorklund, A. (1988) Exp. Brain Res. 70 , 192-208. pmid:3402564 LaunchUrlPubMed ↵ Clarke, D. J., Brundin, P., Strecker, R. E., Nilsson, O. G., Bjorklund, A. & Lindvall, O. (1988) Exp. Brain Res. 73 , 115-126. pmid:3145209 LaunchUrlCrossRefPubMed ↵ Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W. Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., Eidelberg, D. & Fahn, S. (2001) N. Engl. J. Med. 344 , 710-719. pmid:11236774 LaunchUrlCrossRefPubMed ↵ Jeong, S. W., Chu, K., Jung, K. H., Kim, S. U., Kim, M. & Roh, J. K. (2003) Stroke 34 , 2258-2263. pmid:12881607 LaunchUrlAbstract/FREE Full Text ↵ Uchida, N., Buck, D. W., He, D., Reitsma, M. J., Masek, M., Phan, T. V., Tsukamoto, A. S., Gage, F. H. & Weissman, I. L. (2000) Proc. Natl. Acad. Sci. USA 97 , 14720-14725. pmid:11121071 LaunchUrlAbstract/FREE Full Text ↵ Tamaki, S., Eckert, K., He, D., Sutton, R., Executeshe, M., Jain, G., Tushinski, R., Reitsma, M., Harris, B., Tsukamoto, A., et al. (2002) J. Neurosci. Res. 69 , 976-986. pmid:12205691 LaunchUrlCrossRefPubMed ↵ Zhao, H., Yenari, M. A., Cheng, D., Sapolsky, R. M. & Steinberg, G. K. (2003) J. Neurochem. 85 , 1026-1036. pmid:12716434 LaunchUrlPubMed ↵ Barone, F. C. & Feuerstein, G. Z. (1999) J. Cereb. Blood Flow Metab. 19 , 819-834. pmid:10458589 LaunchUrlPubMed ↵ Seri, B., Garcia-Verdugo, J. M., McEwen, B. S. & Alvarez-Buylla, A. (2001) J. Neurosci. 21 , 7153-7160. pmid:11549726 LaunchUrlAbstract/FREE Full Text ↵ Chu, K., Kim, M., Jeong, S. W., Kim, S. U. & Yoon, B. W. (2003) Neurosci. Lett. 343 , 129-133. pmid:12759181 LaunchUrlCrossRefPubMed ↵ Ekdahl, C. T., Classen, J. H., Bonde, S., Kokaia, Z. & Lindvall, O. (2003) Proc. Natl. Acad. Sci. USA 100 , 13632-13637. pmid:14581618 LaunchUrlAbstract/FREE Full Text ↵ Hoehn, M., Kustermann, E., Blunk, J., Wiedermann, D., Trapp, T., Wecker, S., Focking, M., ArnAged, H., Hescheler, J., Fleischmann, B. K., et al. (2002) Proc. Natl. Acad. Sci. USA 99 , 16267-16272. pmid:12444255 LaunchUrlAbstract/FREE Full Text ↵ Aboody, K., Brown, A., Rainov, N., Bower, K., Liu, S., Yang, W., Small, J., Herrlinger, U., Ourednik, V., Black, P., Fracturefield, X. & Snyder, E. Y. (2000) Proc. Natl. Acad. Sci. USA 97 , 12846-12851. pmid:11070094 LaunchUrlAbstract/FREE Full Text ↵ Aarum, J., Sandberg, K., Haeberlein, S. L. & Persson, M. A. (2003) Proc. Natl. Acad. Sci. USA 100 , 15983-15988. pmid:14668448 LaunchUrlAbstract/FREE Full Text ↵ Tran, P. B., Ren, D., Veldhouse, T. J. & Miller, R. J. (2004) J. Neurosci. Res. 76 , 20-34. pmid:15048927 LaunchUrlCrossRefPubMed ↵ Zhang, R. L., Zhang, L., Zhang, Z. G., Morris, D., Jiang, Q., Wang, L., Zhang, L. J. & Chopp, M. (2003) Neuroscience 116 , 373-382. pmid:12559093 LaunchUrlCrossRefPubMed ↵ Englund, U., Bjorklund, A. & Wictorin, K. (2002) Brain Res. Dev. Brain Res. 134 , 123-141. pmid:11947943 LaunchUrlPubMed ↵ Fricker, R. A., Carpenter, M. K., Winkler, C., Greco, C., Gates, M. A. & Bjorklund, A. (1999) J. Neurosci. 19 , 5990-5905. pmid:10407037 LaunchUrlAbstract/FREE Full Text ↵ Gleeson, J. G., Lin, P. T., Flanagan, L. A. & Walsh, C. A. (1999) Neuron 23 , 257-271. pmid:10399933 LaunchUrlCrossRefPubMed ↵ Wennersten, A., Meier, X., Holmin, S., Wahlberg, L. & Mathiesen, T. (2004) J. Neurosurg. 100 , 88-96. pmid:14743917 LaunchUrlPubMed ↵ Windrem, M. S., Nunes, M. C., Rashbaum, W. K., Schwartz, T. H., Excellentman, R. A., McKhann, G., 2nd, Roy, N. S. & GAgedman, S. A. (2004) Nat. Med. 10 , 93-97. pmid:14702638 LaunchUrlCrossRefPubMed ↵ Wu, P., Tarasenko, Y. I., Gu, Y., Huang, L. Y., Coggeshall, R. E. & Yu, Y. (2002) Nat. Neurosci. 5 , 1271-1278. pmid:12426573 LaunchUrlCrossRefPubMed ↵ Hurelbrink, C. B., Armstrong, R. J., Dunnett, S. B., Rosser, A. E. & Barker, R. A. (2002) Eur. J. Neurosci. 15 , 1255-1266. pmid:11982636 LaunchUrlCrossRefPubMed ↵ Shihabuddin, L. S., Horner, P. J., Ray, J. & Gage, F. H. (2000) Soc. Neurosci. 20 , 8727-8735. LaunchUrl
Like (0) or Share (0)